BRBruno M. de Brito Robalo

Bruno M. de Brito Robalo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bruno M. de Brito Robalo has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cohort Profile Update: the Rotterdam Periconceptional Cohort—biomarkers, lifestyle intervention, and artificial intelligence

    by Wietske A P Bastiaansen, Bruno M de Brito Robalo, Melek Rousian, Sam Schoenmakers, Sten Willemsen, Anton Koning, Esther Baart, Annemarie Mulders, Eric Steegers, Régine P M Steegers-Theunissen

  • Open Access

    Longitudinal cortical thickness changes in children with posterior fossa tumors

    by Anne E M Leenders, Szabolcs David, Bruno M De Brito Robalo, Hannah Heckmanns, John H Maduro, Maarten H Lequin, Eelco Hoving, Marita Partanen

    Background Children with posterior fossa tumors (PFTs) are at risk of long-term neurocognitive deficits, yet the impact of tumor grade and treatment intensity on cortical development remains poorly understood. The aim of this study was to determine whether cortical thickness trajectories differ between children with low- versus high-grade PFTs and whether radiation dose influences cortical development in medulloblastoma patients. Methods: We conducted a retrospective longitudinal study of 55 children (37 low-grade, 18 high-grade medulloblastoma) diagnosed between 2018 and 2020. A total of 406 T1-weighted MRI scans acquired up to five years post-diagnosis were processed using CAT12 in SPM12 to estimate cortical thickness. Vertex-wise linear mixed-effects models assessed cortical thickness changes over time, adjusting for age at diagnosis, sex, and hydrocephalus. Within the high-grade group, we evaluated the effect of craniospinal irradiation (CSI) dose (23.4 vs. ≥36 Gy) on cortical development. Results: Children with low-grade tumors showed significant bilateral cortical thinning over time, consistent with typical neurodevelopment. In contrast, medulloblastoma patients treated with surgery, chemotherapy, and radiation therapy showed relative cortical stability across follow-up. Significant group-by-time interactions were observed, with low-grade patients demonstrating greater cortical thinning in parietal, temporal, and occipital regions. No significant differences in cortical trajectories were found between high- and standard-dose CSI subgroups. Conclusions: Cortical development trajectories in pediatric PFT survivors differ by tumor grade and treatment intensity. While low-grade patients exhibit expected maturational thinning, cortical stability in high-grade patients may reflect disrupted neurodevelopment. These findings underscore the need for longitudinal neuroimaging in pediatric neuro-oncology survivorship care.

  • Open Access

    Rethinking Trust in Synthetic Health Data: Lessons from Seven European Research Initiatives (Preprint)

    by Jens Declerck, Dipak Kalra, Antti Airola, Ahmed Youssef Ali Amer, Christos Chatzichristos, Maria del Mar Mañu, Bruno M. de Brito Robalo, Francesco Ghini, Alberto Gutierrez-Torre, Sem Hoogteijling, et al.

    Synthetic data generation (SDG) structured health data is increasingly promoted as a solution to longstanding barriers in health data access. It is offering the promise of privacy-preserving data reuse for research, innovation, and policy. Despite rapid technical advances, the adoption of synthetic health data in real-world settings remains limited. Shaped by challenges around data quality, representativeness, infrastructure readiness, trust, and legal uncertainty, this viewpoint draws on experiences from 7 European research initiatives within the HealthData4EU cluster to reflect on how SDG is being operationalized in practice. It synthesizes cross-project insights to highlight recurring methodological and governance tensions and to examine their implications for trust and responsible use. The analysis argues that trustworthy SDG cannot be achieved through technical optimization alone but requires alignment between evaluation practices, upstream data stewardship, regulatory clarity, and sustained stakeholder engagement. Addressing these conditions is essential for moving synthetic data from experimental pilots toward a credible and sustainable component of European health research ecosystems.


  • Open Access

    Building Trust in Synthetic Health Data: Methodological and Acceptance Challenges across Seven European Projects (Preprint)

    by Jens Declerck, Dipak Kalra, Antti Airola, Ahmed Youssef Ali Amer, Christos Chatzichristos, Maria del Mar Mañu, Bruno M. de Brito Robalo, Francesco Ghini, Alberto Gutierrez-Torre, Sem Hoogteijling, et al.

    BACKGROUND Synthetic data generation (SDG) is increasingly used in health research to address privacy concerns and data sharing barriers, particularly in cross-border and multi-institutional contexts. Despite growing interest, questions remain around the methodological soundness, legal status, and real-world trustworthiness of synthetic health data. OBJECTIVE This paper examines how SDG is operationalized across seven European projects in the HealthData4EU cluster. It identifies common methodological, compliance, and acceptance challenges, and highlights emerging strategies to ensure the quality and utility of synthetic health data. METHODS A qualitative multiple case study approach was used, combining workshop presentations with structured input from each project. Projects were analyzed across four aspects: methodological challenges, data quality assurance, trust and transparency strategies, and contributions to the wider synthetic data ecosystem. RESULTS Results reveal recurring challenges across projects: tension between privacy and utility, lack of shared quality validation standards, institutional readiness gaps, and legal ambiguity under GDPR. Projects employ varied strategies, including federated machine learning and validation pipelines, differential privacy, co-design processes, and metadata transparency tools, but implementation remains uneven. The absence of harmonised legal and evaluation frameworks continues to hinder broader uptake. CONCLUSIONS To scale SDG from isolated pilots to trusted European infrastructure, four priorities are critical: shared evaluation metrics, legal clarity, sustainable platforms, and embedded stakeholder engagement. While rooted in specific projects, the insights offer broader relevance for global SDG efforts, as the core tensions identified are likely to recur across health systems.

  • Open Access

    Unraveling the relations between post-traumatic stress symptoms, neurocognitive functioning, and limbic white matter in pediatric brain tumor patients

    by Anne E M Leenders, Eva Kremer-Hooft van Huijsduijnen, Bruno Robalo, Rosa van Male, Alberto De Luca, Rachèl Kemps, Eelco Hoving, Maarten H Lequin, Martha A Grootenhuis, Marita Partanen

    Pediatric brain tumor patients are at risk of developing neurocognitive impairments and associated white matter alterations. In other populations, post-traumatic stress symptoms (PTSS) impact cognition and white matter. This study aims to investigate the effect of PTSS on neurocognitive functioning and limbic white matter in pediatric brain tumor patients. Sixty-six patients (6–16 years) completed neuropsychological assessment and brain MRI (1-year post-diagnosis) and parents completed PTSS proxy questionnaires (CRIES-13; 1–3 months and 1-year post-diagnosis). Mean Z-scores and percentage impaired (>1SD) for attention, processing speed, executive functioning, and memory were compared to normscores (t-tests, chi-square tests). Multi-shell diffusion MRI data were analyzed for white matter tractography (fractional anisotropy/axial diffusivity). Effects of PTSS on neurocognition and white matter were explored with linear regression models (FDR correction for multiple testing), including age at diagnosis, treatment intensity, and tumor location as covariates. Neurocognition and limbic white matter associations were explored with correlations. Attention (M = −0.49, 33% impaired; P < .05) and processing speed (M = −0.57, 34% impaired; P < .05) were significantly lower than healthy peers. PTSS was associated with poorer processing speed (β = −0.64, P < .01). Treatment intensity, age at diagnosis, and tumor location, but not PTSS, were associated with limbic white matter metrics. Neurocognition and white matter metrics were not associated. Higher PTSS was associated with poorer processing speed, highlighting the need for monitoring, and timely referrals to optimize psychological well-being and neurocognitive functioning. Future research should focus on longitudinal follow-up and explore the impact of PTSS interventions on neurocognitive performance.